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Immune outcomes of sleep disorders: the hypothalamic-
pituitary-adrenal axis as a modulatory factor
Repercussões imunológicas dos distúrbios do sono: o
eixo hipotálamo-pituitária-adrenal como fator modulador
Abst rac t
Objective: To review the literature on the interaction between sleep and the immune system. Method: A search on Web of
Science and Pubmed database including the keywords sleep, sleep deprivation, stress, hypothalamic-pituitary-adrenal axis,
immune system, and autoimmune diseases. Results: On Web of Science, 588 publications were retrieved; 61 references, more
significant and closer to our objective, were used, including original articles and review papers. Conclusion: Sleep deprivation
and immune system exert a bidirectional influence on each other. Since sleep deprivation is considered a stressor, inasmuch as
it induces elevation of cortisol or corticosterone levels in humans and rodents, respectively, and given the well-known
immunosuppressive effect of glucocorticoids, we propose that increased activation of the hypothalamic-pituitary-adrenal axis is a
major mediator of the immune alterations observed in patients with insomnia or in sleep deprived subjects.
Descriptors: Sleep deprivation; Stress; Hypothalamic-pituitary-adrenal axis; Immune system; Autoimmune diseases
Resumo
Objetivo: Revisar a literatura a respeito da interação entre sono e sistema imunológico. Método: Busca no Web of Science e no
PubMed com os descritores: sono, privação de sono, estresse, eixo hipotálamo-pituitária-adrenal, sistema imunológico e doenças
auto-imunes. Resultados: Foram encontrados 588 artigos no Web of Science. As 61 referências mais significativas e mais
relacionadas aos objetivos do estudo foram utilizadas. Foram incluídos artigos originais e de revisão. Conclusão: A privação de
sono e o sistema imunológico exercem e sofrem influências mútuas. A privação de sono é considerada um estressor, uma vez que
induz a elevação do cortisol em seres humanos - ou da corticosterona em roedores. Os glicocorticóides, por sua vez, exercem um
efeito imunossupressor. Por essas razões, foi proposto que o aumento da ativação do eixo hipotálamo-pituitária-adrenal seja um
importante mediador das alterações imunológicas observadas em pacientes com insônia ou privados de sono.
Descritores: Privação de sono; Estresse; Eixo hipotálamo-pituitária-adrenal; Sistema imunológico; Doenças auto-imunes
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Int roduct ion
The mammalian organism is gifted with a system whose
main function is to maintain the inner balance. This
neuroendocrine system, known as the hypothalamic-pituitary-
adrenal (HPA) axis, is mobilized every time there is a threat to
life, regardless of whether it is real or imaginary, so that
appropriate behaviors will be displayed and metabolic changes
will take place to provide the energy necessary to deal with
such situations. Inappropriate, either hypo- or hyperactivation
of the HPA axis will lead to illness (Figure 1), including sleep-
and immune-related disorders. Therefore, we propose that the
HPA axis could mediate the relationship between sleep
disorders, mainly insomnia, and the immune system.
hormone, the growth hormone. Sleep onset is associated with
an increase in circulating levels of some cytokines, with peak
values occurring 2.5 hours after sleep onset.
2
 The circadian
rhythm of pro-inflammatory cytokines may explain, at least in
part, the nighttime exacerbations of immunoinflammatory
disorders such as asthma and rheumatoid arthritis.
The HPA axis and the stress response
The secretion of corticotrophin-releasing factor (CRF),
adrenocorticotropin hormone (ACTH), cortisol or corticosterone
(CORT), noradrenaline (NA), and adrenaline is also related to
wake-sleep cycle, but is primordially controlled by circadian
rhythm. Thus, peak activity of both HPA axis and sympathetic
autonomic nervous system occur shortly before the active period
(daytime for human beings and nighttime for rodents), and
minimum activity is observed shortly before sleep
1
 (Figure 3).
Therefore, the activity of the HPA axis is increased in
preparation to deal with stress and in response to actual
stressful events. Thus, it is vital that the system is activated
when necessary, but even more so, that the system gets shut
down as soon as the situation is dealt with. The most important
regulator of this system is its end product, the glucocorticoid
cortisol (in primates and human beings) or corticosterone (in
rodents). In a classical review paper, Munck et al. have
proposed that “the physiological function of stress-induced
increases in glucocorticoid levels is to protect not against
the source of stress itself, but against the normal defence
reactions that are activated by stress. Glucocorticoids
accomplish this function by turning off those defence
reactions, thus preventing them from overshooting and
themselves threatening homeostasis”.
3
 This means that if
unchecked by the glucocorticoid negative feedback system,
the activation of the HPA axis may itself become detrimental.
Glucocort icoids (GCs), in fact, exhibit permissive and
suppressive effects that are complementary, for the former pre-
pare or prime the defence mechanisms for action and the
latter limit these actions, by binding to type II or glucocorticoid
receptors (GR) to exert this negative feedback action (Figure 4).
GR are ubiquitously distributed in the CNS and periphery,
inc luding the immune sys tem, whereas type I  o r
mineralocorticoid receptors (MR) show a more restricted
distribution, being located in the limbic system, hippocampus
and septum (Table 1). Behavioral and neuroendocrine studies
suggest that MR are involved with the permissive and/or
circadian actions of GCs, whereas GR are responsible for
the suppressive effects, restoring the disturbed homeostasis
resulting from stress exposure.
4-6,8
Hormones of the HPA axis and sleep
Classically, activation of the HPA and/or the sympathetic
nervous systems results in waking. In human beings or in
animals, these hormones are associated with attention,
vigilance and arousal. This plethora of effects is intuitive for
nobody will feel asleep in face of danger or a life threat.
As mentioned above, the lowest levels of cortisol are obtained
during delta sleep. This might suggest that cortisol release is
inhibited by delta sleep, as had been believed for a long time.
9
However, a recent study has demonstrated that, contrary to
previous belief, is the lack of cortisol pulse that allows delta
sleep to occur, since temporally, lack of cortisol pulse prece-
des delta sleep.
10
Another interest ing aspect refers to changes in the
sensitivity of the axis throughout the sleep cycle, inasmuch
Human sleep
The sleep in human beings is generally divided in two main
phases: Rapid Eye Movement (REM) sleep and Non-REM
sleep. Non-REM sleep can be subdivided in four phases: stages
1 and 2, and stages 3 and 4, which, together, are known as
delta sleep. As shown in Figure 2, the stages follow a sequence
in which there is a predominance of delta sleep during the
first half of the night and longer and more frequent events of
REM sleep during the last third of the night.
Sleep evolves in cycles of NREM and REM phases, which,
together, take approximately 90 minutes. During these cycles,
specific physiological events take place, such as release of
growth hormone during delta sleep, whereas the lowest activity
of the HPA axis is observed during delta sleep.
1
 Cytokines show
a nocturnal profile similar to that found for the sleep-dependent
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as pituitary response to a corticotrophin-releasing factor/
a r g in ine  vasop ress in  (CRF /AVP)  cha l l enge  in  hea l thy
volunteers kept awake is higher than when they are allowed
to s leep, regardless of  the t ime of  s leep depr ivat ion,
11
suggesting that reduced response of the pituitary to CRF is
not merely a reflex of circadian influences, but it is rather
inhibited by sleep onset.
12
Numerous findings have confirmed the effects of CRF on sleep.
In animals, intra LC injection of CRF stimulates the firing rate of
these neurons,
13
 which are known to be more active during
waking.
14
 Moreover, i.c.v. administration of low doses of CRF
results in EEG waking pattern, whereas blockade of CRF receptors
or inactivation of CRF synthesis reduces spontaneous waking and
increases delta sleep in rats treated during their active period.
15-16
 Additional evidence for the role of CRF on the regulation of
waking is given by Lewis rats, which present a genetic deficiency
in CRF production. Therefore, these rats show a hypoactive
HPA axis and, consequently, they also spend less time in
waking and more time in slow wave sleep than rats with a
normal HPA axis activity.
17
 Blockade of cortisol synthesis
with metyrapone, an inhibitor of the 11β-hydroxilase, leads
to augmented activity of the CRF system (due to a chemical
removal of the negative feedback system) and, as a result,
reduction of delta sleep.
18
Administration of CRF to human beings also impairs
sleep, but the consequences also appear to be age-
dependent. Whilst young men (20-28 years old) only
exhibit increased waking time during the second half of
the night by virtue of reduced REM sleep, middle aged
volunteers (37-54 years o ld)  d isplay more severe
impairments, including augmented waking time after sleep
onset, throughout the entire night.
19
In regards to the effects of GCs on sleep, data are
scarce and sometimes difficult to interpret due to the
close relationship among the components of the HPA
axis. Therefore, high levels of GCs might lead to direct
outcomes, which could also be the resul t  of  CRF-
dependen t  r egu la t i on .  Fo r  i ns t ance ,  r epea ted
administration of hydrocortisone increases theta and
delta frequencies (synchronized activity at the EEG),
indicating increased delta sleep. On the contrary, REM
sleep is reduced. These effects may be caused by an
inhibition of CRF actions on sleep.
20
However, it must be emphasized that optimum levels of
cortisol are necessary for good quality sleep. For instance,
in rats, adrenalectomy leads to augmented slow wave sleep,
but reduces REM sleep.
21-22
 Likewise, patients with adrenal
insufficiency due to Addison’s Disease present impaired REM
sleep, and treatment with hydrocortisone normalizes these
disturbances, increasing the percentage and reducing the
latency to REM sleep.
23
Patients under chronic treatment with methylprednisolone
(a GR agonist) exhibit reduction of REM sleep latency,
augmented REM sleep time, and a dislocation of slow-wave
sleep (SWS) from the first to the second half of the sleep
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period. In contrast, the MR antagonist canrenoate only reduces
SWS.
24-25
 Mifepristone, a mixed GR progesterone receptor
antagonist, diminishes the SWS and REM time with increase
of sleep latency. The combination of dexamethasone and
spironolactone, a MR antagonist, reduces REM sleep; and
dexamethasone followed by mifepristone diminishes total sleep
time (SWS and REM) and increases the arousals during the
night.
26
 In respect to the weak influence of MR receptors on
sleep control, another study has shown that the MR agonists
deoxycorticosterone and spironolactone do not affect sleep EEG
substantially in human beings.
27
The results presented above suggest that corticosteroid-
induced changes in SWS are mediated via MR-like central
receptors in humans, whereas changes in REM sleep involve
GR-mediated events.
The immune system and the HPA axis
GCs represent the most powerful  endogenous ant i -
inflammatory and immunosuppressive agent, interfering with
virtually every step of the immunoinflammatory responses.
Because GCs are regarded as the most effective anti-
inflammatory drugs, they were considered, for many years, as
purely immunosuppressant agents. Today, the
immunomodulatory role of the GCs is well recognized, such
as modulating T and B-cell maturation, selection, proliferation
and influence on the trafficking, and activation of inflammatory
cells by inhibiting the expression of adhesion molecules and
major histocompatibility complex (MHC) class II antigens in
leukocytes. In addition, GCs inhibit the production of a wide
range of cytokines including IL-1, IL-2, IL-6 and TNF-α and
decrease the effects of certain inflammatory molecules on
various target tissues. At physiological concentrations, GCs
inhibit T helper-type I (Th1) and enhance Type 2 (Th2) cytokine
production, thus shifting immune responses from Th1 to a
Th2 pattern.
28
 Th1 and Th2 responses are defined by the
different types of cytokines secreted.
29
 For instance, Th1
response is defined by secretion of pro-inflammatory cytokines,
whereas Th2 secretes the major anti-inflammatory cytokines.
Both responses play an important role in the course of an
immune response, insofar as Th1 response promotes cellular
immunity, whist the Th2 initiates humoral immunity and
counteracts the Th1 response. The Th1/Th2 unbalance is a
crucial factor that determines the manifestation of some
diseases such as autoimmune and inflammatory ones. Some
results strongly suggest that a high reactivity of the HPA axis
is associated with a high capacity to generate Th2-type
responses, whereas low HPA axis reactivity goes with a higher
capacity to generate Th1-type response.
30
The HPA axis-immune system relationship exhibits a bimodal
pattern in which GCs may function as either an inhibitory or
permissive factor depending on i ts circulat ing levels.
Disturbances at any level of the HPA axis or on the action of
GCs results in immune system imbalance, which consequently
is harmful to the organism. GCs act as modulators of the
immune system, for either excess or deficient release are
associated with illness. On one hand, hyper-stimulation of
the HPA axis, with excessive secretion of GCs, results in
intense immunosuppression and increased susceptibility to
infection; on the other hand, insufficient secretion of GCs
leads to inflammatory and autoimmune diseases.
31
Let us consider, for instance, a situation in which the
stressful stimulus is an injury to the skin. Appropriate stress
response, with adequate levels of cortisol and adrenaline,
results in vasoconstriction to prevent hemorrhage, increased
traffic of leukocytes to fight any possible antigen and increased
production of fibrinogen to help wound healing.
32
 CRF also
exhibits this bimodal pattern of effect on the immune system,
since it decreases T cell proliferation and natural killer (NK)
cell cytotoxicity, but can also enhance B cell proliferation
and the prol i ferat ive lymphocyte response to var ious
mitogens.
8
 Therefore, in an initial demand, these hormones
are immunostimulant, rather than immunosuppressive. The
role of GCs in establishing homeostasis includes their
immunosuppressive effect, for it can reduce the likelihood of
autoimmune overshoot. Polyclonal responses are induced by
immune chal lenges,  which may increase the r isk o f
autoimmunity. Under physiological conditions GCs are
se lec t ive,  “sculpt ing”  the immune response so that
superfluous or autoimmune-pron e components are selectively
inhibited, due to the preferential target ing by GCs of
lymphocytes that are less active or that produce antibodies
with lower affinities for the antigen.
8
The use of animal models has led to many important findings
highlighting how essential the stress response is for both the
physiological regulation of the immune system and for the
development and manifestat ion of  inf lammatory and
autoimmune diseases. The rat strains Lewis (LEW/N) and
Fischer (F344/N) are widely used to assess neuroendocrine
regulation of many aspects of autoimmunity. LEW/N rats are
more susceptible to the development of autoimmune/
inflammatory disorders in response to antigenic stimuli, since
this strain exhibits a hyporesponsiveness of the HPA axis. The
F344/N strain, on the contrary, is relatively resistant to these
disorders due to augmented activity of the HPA axis.
33
Another extremely intriguing feature is the bidirectional
relationship between the HPA axis and the immune system.
Endogenous GCs production is tightly regulated with activation
of the immune system, as part of the systemic stress response.
Inflammatory and immune responses lead to a rapid activation
of the HPA axis and production of GCs. The activation of the
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HPA axis was found to occur on the hypothalamic level
34
 and
via the pituitary gland but some data have indicated that the
adrenal may be a direct target for cytokine action during the
immune response.
35
 Other cytokines, including IL-2, IL-6,
tumor necrosis factor-a (TNF-α), and interferon-γ (IFN-γ), have
been shown to stimulate the adrenocortical axis, although
none with the potency of IL-1.
8
 The increased release of GCs
in the course of immune challenges represents an important
regulatory mechanism, providing a negative feedback in
response to the overproduction of cytokines.
Inadequate sleep, the immune system and the
HPA axis
The interaction between sleep and immune system has been
systematically studied in the last decade. This bidirectional
relationship is based on the lethargy and strong sleepiness
that occur during infections and inflammatory conditions and
on the augmented susceptibility to infections as a consequence
of sleep deprivation.
An ever-growing number of studies have been performed in
order to assess the impact of inadequate sleep on the quality
of life, morbidity and mortality. For instance, a retrospective
study conducted in Denmark has demonstrated that nighttime-
working women showed augmented risk for breast cancer than
daytime-working women.
36
 In an elegant in vitro study, the
effects of cortisol alone or in association with melatonin on
human lymphocyte proli feration after st imulation with
concanavalin A (CON A) have been studied. Incubation with
either cortisol alone (such as during the day) or with the
combination of cortisol and melatonin (such as in shift workers)
inhibits even further the lymphocyte proliferation, indicating
that disruptions of the balance between cortisol and melatonin
are detrimental to optimum activity of the immune system.
37
Laboratory studies have shown that partial sleep deprivation
following immunization against hepatitis A reduces the
production of antibody titers approximately 4 weeks after
immunization.
38
 In addition, partially sleep-deprived individuals
also exhibit impairment of antibody production against Influenza
virus. The antibody titers were determined in the fourth week
postimmunization, at a time when production reaches a peak.
39
These findings highlight the importance of ideal sleep, given
that the effects of sleep deprivation can be manifested much
later. These effects may be at least partly explained by the
well-known stressful nature of sleep deprivation, which has
been shown both in human beings
40
 and animals.
41-42
Sleep disorders in which sleep deprivation is a major feature,
such as insomnia and sleep apnea, result in major alterations
in the immune system, which may be mediated by the
augmented activity of the HPA axis and/or the sympathetic
nervous system. Stress is considered one of the major triggering
factors of insomnia, inasmuch as epidemiologic studies report
that primary insomnia patients attribute the onset of the disorder
to some stressful event.
43-45
 Chronic internalization of feelings
may cause a psychological and physiological arousal, leading,
ultimately, to insomnia. Some authors propose that increased
activity of the HPA axis produces sleep fragmentation, which,
in turn, elevates circulating levels of cortisol,
46
 whereas others
43
bel ieve in the existence of  a mechanism of cor t ical
hyperarousal in insomniac patients triggered by emotional,
cognitive and physiological components. Therefore, the
hyperactivity exacerbates vigilance and impacts negatively on
sleep, thus forming a vicious circle in which difficulty to sleep
becomes the stressful factor itself.
47
 This hypothesis has been
confirmed by the positive correlation between elevated levels
of cortisol, increased activity of the sympathetic system and
time of waking in chronic insomniacs.
48
 However, there has
always been a question of whether insomnia leads to increased
HPA activity, or increased activity of the HPA axis is a risk
factor for the development of stress-induced insomnia. It has
been shown that in chronic insomniacs, plasma levels of ACTH
and cortisol are elevated exactly during the nadir of the
circadian rhythm, i.e., between 10 pm and 2 am, without
any change in the circadian pattern of secretion but a flattening
of the amplitude. The authors have interpreted these results
as indicative that increased activity of the HPA axis is responsible
for poor sleep in insomniacs, because if it were a response to
bad sleep quality, ACTH and cortisol levels should be elevated
in the morning as a response to the poor sleep.
49
In regards to the correlation between immune alterations
and insomnia, it has been shown that chronic insomnia patients
exhibit a reduction of CD3+, CD4+ and CD8+ cells
50
 and a
predominance of Th2 response, i.e., enhanced humoral
immune response.
51
 It is worth emphasizing that alterations
in Th1/Th2 balance are characteristic of autoimmune diseases.
One of the major effects of GCs on the immune system is the
suppression of cellular immunity and enhancement of humoral
immunity, a process that is also driven by the Th1 to Th2 shift
in cytokine profile production. Therefore, increased levels of
cortisol could at least partly explain the change in Th1/Th2
response in insomniac patients.
Concluding remarks
Sleep is regulated by a myriad of neurotransmitters and
hormones that work in concert to guarantee that such funda-
mental process is not severely disturbed by environmental
factors. Likewise, a well-preserved immune system is essential
for survival. Failure in maintaining these systems functioning
in perfect harmony can be regarded as a stressor, thus leading
to activation of the HPA axis, which can result in further
disruptions. Therefore, the adequate stress response mounted
by an individual is vital for the perfect functioning of these
systems. Thus, although many other mediators play a role in
sleep and the activity of the immune system, we believe that
exaggerated secretion of GCs is the major mediator of sleep
disorders-induced deficits in the immune system.
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